Eyad Abochale, MD
Pulmonary Disease · Little Rock, ARNPI 1376577387
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 627 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 627 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$745
- Mylan Specialty L.p.$664
- plus $3K from 36 others
What the payments were for
- Food & beverage$11,341100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$134
- OFEV$125
How this compares
$11,343 in reported general payments places this provider in the 80th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 56 | $753,390 |
| OpsumitMacitentan | 50 | $626,129 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 27 | $413,621 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 493 | $387,869 |
| Dupixent PenDupilumab | 92 | $385,250 |
| UptraviSelexipag | 11 | $257,112 |
| NucalaMepolizumab | 35 | $228,810 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 284 | $196,866 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 11 | $173,793 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 98 | $58,110 |
| TezspireTezepelumab-Ekko | 13 | $57,928 |
| AdcircaTadalafil | 13 | $50,739 |
| Spiriva RespimatTiotropium Bromide | 82 | $45,840 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 63 | $38,914 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $37,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,558 | $896,253299 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,010 | $883,24161 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,518 | $700,331703 claims |
| Insmed, Inc.Arikayce | $191 | $413,62127 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $1,985 | $291,407426 claims |
| United Therapeutics CorporationAdcirca | $104 | $50,73913 claims |
| Johnson & JohnsonXarelto | $108 | $6,13511 claims |
| PfizerPaxlovid | $171 | $1,42913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Nikhil MeenaLittle Rock$63K
- Hanan Khadam-MakhoulLittle Rock$15K
- Raghu ReddyLittle Rock$13K
- Krishna Siva Sai KakkeraLittle Rock$11K
- Samer HomsiLittle Rock$9K
- Nathan HillLittle Rock$9K
- Jose CaceresLittle Rock$6K
- Moeezullah BegLittle Rock$5K
- Rosa ArancibiaLittle Rock$4K
- Nancy RectorLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.